Amphastar Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M | $349.8M | $322.4M | $294.7M |
| Cost of Revenue | $363.8M | $358.1M | $293.3M | $250.1M | $238.0M | $206.5M | $190.4M | $187.7M |
| Gross Profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M | $143.3M | $131.9M | $107.0M |
| Gross Margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% | 40.9% | 36.3% |
| Operating Expenses | ||||||||
| Research & Development | $85.8M | $73.9M | $73.7M | $74.8M | $60.9M | $67.2M | $68.9M | $57.6M |
| SG&A Expense | $85.9M | $56.7M | $51.5M | $45.1M | $51.4M | $50.4M | $50.3M | $49.9M |
| Operating Income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M | $11.0M | $-39.0K | $-8.6M |
| Operating Margin | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | 3.1% | 0.0% | -2.9% |
| Interest Expense | — | — | $27.2M | $1.8M | $885.0K | $374.0K | $119.0K | $243.0K |
| Pretax Income | $123.6M | $189.8M | $171.4M | $116.0M | $84.1M | $4.6M | $60.2M | $-9.9M |
| Income Tax Expense | $25.5M | $29.7M | $31.8M | $23.5M | $20.6M | $3.5M | $13.7M | $-3.3M |
| Net Income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | $-5.7M |
| Net Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | -1.9% |
| EPS (Basic) | $2.10 | $3.29 | $2.85 | $1.88 | $1.30 | $0.03 | $1.04 | $-0.12 |
| EPS (Diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | $-0.12 |
| Shares Outstanding (Basic) | 46.7M | 48.4M | 48.3M | 48.6M | 47.8M | 47.0M | 47.0M | 46.4M |
| Shares Outstanding (Diluted) | 48.2M | 52.1M | 53.0M | 52.4M | 49.8M | 49.1M | 49.9M | 46.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |